Projekt · Dnr 2019-03500 · Källa: Vinnova
E!113292, nOVAB, Göteborgs Universitet
- Koordinator
- Göteborgs universitet, Avdelningen för onkologi
- Projekttid
- 2019-10-01 till 2022-09-30 (avslutat)
- Beviljat bidrag
- 2 217 459 SEK
- Diarienummer
- 2019-03500
Beskrivning
We recently discovered a specific epitope (referred to herein as “t334”-the target) of a monoclonal antibody that blocks a tumour cell-specific target, leading to cell death and reduced tumour growth via a novel cancer pathway. This target belongs to a family of transmembrane serine/threonine tyrosine kinases. The target t334 gene expression was increased in cancer cells compared with normal tissues. The aim now is to develop this new chemical entity (TTX33o) into a treatment for solid tumours, with an initial focus on gynecological cancers. The clinical significance of the candidate gene was analyzed using TMA consisting of 204 stage I and II ovarian tumors, and 450 aggressive stage III and IV ovarian tumors. Cellular localization of the candidate protein was in the nucleus and the cytoplasm but to a larger extent to the nucleus. We observed unfavorable outcome for patients with samples containing high protein expression of the candidate gene in the cytoplasm than in the nucleus. The same pattern of expression is seen breast tumors. Kidney cancers showed candidate gene cellular localization in the cytoplasm and nucleus.
Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.
Liknande
-
E!11481, E-OxidoCurin, HDXperts AB
HDxperts AB · 2017-10-01 · 4 888 259 SEK · Projekt
All the goals of the project were fulfilled. 1) A new water-soluble lead compound LCTA2940 was synthesized. 2) The TrxR1 target was validated, and the mechanism of interaction and ROS dependent action was elucidated. 3) Using proteomics, we identified additional targets. 4) In vivo LCTA2940 effectiv…
-
Preklinisk utveckling av MTHFD2 hämmare för behandling av cancer
One-carbon Therapeutics AB · 2022-04-01 · 3 000 000 SEK · Projekt
The overall goal for the project was to progress the development of novel cancer therapy from the preclinical to the clinical stage and enable first-in-human clinical trials of MTHFD1/2 inhibitors. The project has successfully executed work packages and delivered milestones as described in the appli…
-
Procurement of a spatial multiomics platform
Uppsala universitet · 2026-03-31 · sista anbudsdag 2026-05-05 · 3 500 000 SEK · Upphandling
The research group at IGP, Uppsala University, seeks to establish an advanced spatial multiomics platform to support ongoing projects in spatial biology and cancer immunology. The system will enable multiplexed, high-resolution protein detection and RNA within tissue architecture, facilitating quant…
-
Identification of target agents for cancer diagnostics and vaccines
Göteborgs universitet · 2002-06-30 · 4 000 000 SEK · Projekt
-
E!7268, PRE-CISE, Akiram Theraputics AB
Akiram Therapeutics AB · 2025-03-15 · 5 000 000 SEK · Projekt
Vårt syfte är att utveckla in nästa generations pre-targeted radiotheranostic (PRT) for precisionsbehandling av cancer. "AKI-TINE" kommer för första gången att kombinera selektivitet och specificitet av AKIR001 (en fullstor IgG1-antikropp som binder till CD44v6, ett cancer-antigen) med pre-targeting…